CD20 positive

P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

Later, the patient received systemic chemotherapy with R-CHOP for eight cycles...This case presents unique features such as chronic abdominal pain and anorexia, which can lead to misdiagnosis due to a broad differential. There is a need to provide knowledge of primary colon lymphoma to ensure early diagnosis and favorable outcomes.

P1/2, N=439, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Jul 2041

P1/2, N=38, Recruiting, Yazeed Sawalha | Trial completion date: Dec 2028 --> Oct 2027 | Trial primary completion date: Dec 2026 --> Aug 2027

The postoperative course was complicated by sepsis, respiratory failure, and prolonged ileus. This case highlights the importance of considering primary gastrointestinal lymphoma in the differential diagnosis of bowel perforation and acute surgical abdomen, particularly in elderly patients presenting emergently.

This case highlights the diagnostic challenge of primary gastrointestinal ENKL in patients presenting with abdominal pain and hematochezia in the absence of computed tomography (CT) abnormalities. Persistent unexplained abdominal pain should prompt consideration of rare ulcerative small bowel diseases, including ENKL, particularly when perforation is a potential complication. Early multidisciplinary intervention is essential to improve the outcomes of this devastating condition.

P1, N=30, Suspended, Beijing Boren Hospital | Initiation date: Apr 2026 --> Sep 2026 | Recruiting --> Suspended

Mature TLS and PD-L1 TC are independent predictors of poor treatment outcomes, and PD-L1 IC is an independent predictor of good treatment outcomes, in patients with locally advanced ESCC receiving neoadjuvant chemoradiotherapy.

P1/2, N=106, Completed, Association International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed

The patient received rituximab-based chemotherapy followed by autologous stem cell transplantation, along with surgical resection for lung adenocarcinoma. She has remained alive for more than 24 months without disease progression. Additionally, we conducted a literature review to enhance clinical awareness of this rare concurrent condition of CD20-positive MEITL and lung adenocarcinoma.

It highlights the importance of integrating clinical findings with flow cytometry, imaging, cytogenetic, and molecular data in establishing the diagnosis. Even when peripheral blood findings suggest a low disease burden, imaging may better define the extent of disease and support appropriate clinical assessment, particularly in elderly patients at risk for complications related to splenomegaly.